PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

2000000977-9.1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/495, 31/535

A1

(11) International Publication Number: WO 99/13877

(43) International Publication Date: 25 March 1999 (25.03.99)

(21) International Application Number: PCT/SE98/01601

(22) International Filing Date: 9 September 1998 (09.09.98)

(30) Priority Data:
9703375-7 18 September 1997 (18.09.97) SE

(71) Applicant *(for all designated States except US)*: ASTRA AKTIEBOLAG [SE/SE]; S–151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BERG, Stefan [SE/SE]; Astra Arcus AB, S–151 85 Södertälje (SE). ROSS, Svante [SE/SE]; Astra Arcus AB, S–151 85 Södertälje (SE). THORBERG, Seth–Olov [SE/SE]; Astra Arcus AB, S–151 85 Södertälje (SE).

(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S–151 85 Södertälje (SE).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: A COMBINATION OF A 5–HT REUPTAKE INHIBITOR AND A h5–HT$_{1B}$ ANTAGONIST OR PARTIAL AGONIST

(57) Abstract

The invention relates to a combination of a first component (a) which is a 5–HT reuptake inhibitor and a second component (b) which is selective h5–HT$_{1B}$ antagonist or partial agonist having formula (I) wherein X is CH_2, O; Y is CONH, NHCO; R_1 is H, C_1–C_6 alkyl, C_3–C_6 cycloalkyl; R_2 is H, C_1–C_6 alkyl, C_1–C_6 alkoxy, halogen; R_3 is (1), (2), (3), CF_3; R_4 and R_5 independently are H, or C_1–C_4 alkyl, as racemate, *R*–enantiomer or *S*–enantiomer, and said components (a) and (b) being in the form of free bases, solvents or pharmaceutically acceptable salts thereof, the preparation thereof, pharmaceutical formulations containing said combinations, use of and method of treatment of affective disorders such as depression, anxiety and OCD with said combination as well as kit containing said combination.



(I)

